Company intelligence / Profile preview

Ye Bei

Shanghai, Shanghai, China

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Yebei Bio is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of mRNA-based therapeutics and vaccines. Founded in 2021, the company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to create a diverse pipeline targeting infectious diseases, oncology, and protein replacement therapies. Its lead program, YB-101, is an mRNA vaccine for COVID-19 that has entered Phase 1 clinical trials. Yebei Bio is backed by prominent venture capital firms including Sequoia China, Hillhouse Capital, and GL Ventures. The company aims to address unmet medical needs through innovative RNA technologies and efficient delivery systems.

Therapeutic areas: Infectious DiseasesRare DiseasesOncology
Modalities: mRNA-based drugsBiologicLipid nanoparticle delivery therapy
Industry: Biotech

Beyond the preview

Go deeper on Ye Bei.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ye Bei.

Explore the full profile